TYZAVAN Drug Patent Profile
Which patents cover Tyzavan, and when can generic versions of Tyzavan launch?
Tyzavan is a drug marketed by Hikma and is included in one NDA. There are six patents protecting this drug.
The generic ingredient in TYZAVAN is vancomycin hydrochloride. There is one drug master file entry for this compound. Thirty-seven suppliers are listed for this compound. Additional details are available on the vancomycin hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Tyzavan
A generic version of TYZAVAN was approved as vancomycin hydrochloride by FRESENIUS KABI USA on March 17th, 1987.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for TYZAVAN?
- What are the global sales for TYZAVAN?
- What is Average Wholesale Price for TYZAVAN?
Summary for TYZAVAN
| US Patents: | 6 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 2 |
| What excipients (inactive ingredients) are in TYZAVAN? | TYZAVAN excipients list |
| DailyMed Link: | TYZAVAN at DailyMed |
Pharmacology for TYZAVAN
| Drug Class | Glycopeptide Antibacterial |
US Patents and Regulatory Information for TYZAVAN
TYZAVAN is protected by six US patents.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hikma | TYZAVAN | vancomycin hydrochloride | SOLUTION;INTRAVENOUS | 211962-005 | May 13, 2020 | RX | Yes | Yes | 10,849,956 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Hikma | TYZAVAN | vancomycin hydrochloride | SOLUTION;INTRAVENOUS | 211962-001 | Feb 15, 2019 | RX | Yes | Yes | 10,039,804 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Hikma | TYZAVAN | vancomycin hydrochloride | SOLUTION;INTRAVENOUS | 211962-004 | Feb 15, 2019 | RX | Yes | Yes | 11,628,200 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Hikma | TYZAVAN | vancomycin hydrochloride | SOLUTION;INTRAVENOUS | 211962-001 | Feb 15, 2019 | RX | Yes | Yes | 11,517,609 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Hikma | TYZAVAN | vancomycin hydrochloride | SOLUTION;INTRAVENOUS | 211962-004 | Feb 15, 2019 | RX | Yes | Yes | 10,849,956 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Hikma | TYZAVAN | vancomycin hydrochloride | SOLUTION;INTRAVENOUS | 211962-002 | Feb 15, 2019 | RX | Yes | Yes | 11,517,609 | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for TYZAVAN
See the table below for patents covering TYZAVAN around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Australia | 2015341763 | ⤷ Start Trial | |
| Brazil | 112017009405 | ⤷ Start Trial | |
| Canada | 2964524 | ⤷ Start Trial | |
| Chile | 2017001139 | ⤷ Start Trial | |
| China | 107073072 | ⤷ Start Trial | |
| Colombia | 2017005391 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch